The clinical and epidemiological burden of chronic lymphocytic leukaemia.
about
Imatinib for treating newly diagnosed chronic myeloid leukemia patientsImatinib for treating patients with chronic myelogeneous leukemiaThe value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.Alemtuzumab for B-cell chronic lymphocytic leukemia.Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis.Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemiaPrevalence of monoclonal B-cell lymphocytosis: a systematic review.B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in GreeceTLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phaseSurvival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection.Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units.An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemiaOncohematological diseases in the Vale do Paraíba, State of São Paulo: demographic aspects, prevalences and incidencesA phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.Skin lesions in chronic lymphocytic leukemia.Bilateral Tonsillar Enlargement as a First Manifestation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with an Unusual Interfollicular Pattern of Infiltration.Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomasGenetic differences between Asian and Caucasian chronic lymphocytic leukemia.Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialRituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.Monoclonal B-cell lymphocytosis: a brief review for general clinicians.Rituximab for chronic lymphocytic leukemia.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility.Fetuin-A levels and free leptin index are reduced in patients with chronic lymphocytic leukemia: a hospital-based case-control study.Emerging immunological drugs for chronic lymphocytic leukemia.Personalized Drug Analysis in B Cell Chronic Lymphocytic Leukemia Patients.Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.Current Treatment of Chronic Lymphocytic Leukemia.Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.Rituximab for the treatment of patients with chronic lymphocytic leukemiaSmall lymphocytic lymphoma obscuring microscopic tonsillar squamous cell carcinoma: an unknown occurrence with a known primary.Hematologic malignancies: an opportunity to fill a gap in cancer surveillance.
P2860
Q24186877-64FEDD75-92CA-4327-B0FB-64BC50E88C75Q24241730-D78FF51B-6A3F-419F-8DB9-5BDBF83F5303Q31033615-0B339926-81CC-4A03-8ADE-734107AC2736Q33375915-658701B4-DE2D-44AE-914F-5874808B3DF8Q33380135-E7DADD16-0AF0-438F-86C5-BC5F67F43DACQ33409149-1F5F356A-D963-4B4E-82E6-6EA5AA76F3E5Q33442438-D93A63F2-8915-42AB-B253-EAA28678D944Q33579784-B1455095-95D6-4199-B271-C16F21DDF141Q34179480-5BB6415D-24FB-4B9D-B2B7-5F10972F460FQ34236960-740846AD-9780-4EF2-AE1A-6CBD7F3BF603Q35001834-BEF8E889-69C0-432E-8D71-F0F2237E7D5EQ35861964-FF2BD06B-1DD6-4577-AE0A-DED4D6629700Q36017262-54B433C0-C7BD-4390-BBA1-A98FF1A8DCA5Q36110555-A3FACAAC-B562-4B78-AAC9-ACB34D5BB29BQ36208343-21E0242B-A32F-4274-BA8A-6F8EAA10CF79Q36303608-4AE5BD94-DFA2-4615-892E-609640F41BDFQ36462468-567D22D4-ABF1-4312-A1B4-3D131DB1DA11Q36519986-2FD464CC-EB7F-4741-9C88-564840CBC007Q36547670-E2BB6C9E-D6F3-4A6A-B0D2-9356A327CCA3Q36814959-0A2B7E4D-099E-49F3-B6A1-4073F41EFE2FQ37048488-EA45B01F-F82A-4FF5-B4A5-F70C576104C9Q37058203-814411E9-7201-4326-844E-C4EE746012DBQ37178396-7E9D4854-28FB-40DF-B21F-0BACB2CA4216Q37267608-0EBBF322-1961-4F89-8EB2-AE6CE70333B4Q37387647-DE8EF69C-9A74-47E0-A357-D30693F41A76Q37799820-853E1720-BAE1-4D72-882E-F0D796E12390Q37900875-025A5066-A287-4F77-BD34-8E3B12953DCDQ37988562-E3BDA05F-FA29-4DBD-86A4-692F8F1A30F9Q38068494-36A023CA-1764-4205-B0DF-C361443C1BA3Q38228728-77A79D85-BE2E-4C0F-B4FE-71DC8B760C11Q38296806-5FBF8AEC-5C79-4CF1-8AF6-0A989286A95FQ38543771-3B58B212-8A94-4668-A96D-F5F392448254Q38800971-A49954F2-4F90-46AD-AAF5-C8E9C5F55244Q38872460-3322B017-ABC9-44E7-93A8-1875839CDB8BQ39129372-7D3AD86C-4B2F-4E43-AE50-5A63F36B3D3BQ39883910-23CAF5DE-B3E9-4FFD-AC14-77BADFF25F66Q40736899-7D425893-912E-48D8-8E46-FB6C05ED78D2Q41241909-3504ED2A-BA46-40FF-B0BE-26F987480444Q41856030-541FCDCC-C407-4704-83AA-BA7D9E164238Q43676080-7D359C84-7A29-4CF4-8B39-BDB8C49427D4
P2860
The clinical and epidemiological burden of chronic lymphocytic leukaemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The clinical and epidemiological burden of chronic lymphocytic leukaemia.
@ast
The clinical and epidemiological burden of chronic lymphocytic leukaemia.
@en
type
label
The clinical and epidemiological burden of chronic lymphocytic leukaemia.
@ast
The clinical and epidemiological burden of chronic lymphocytic leukaemia.
@en
prefLabel
The clinical and epidemiological burden of chronic lymphocytic leukaemia.
@ast
The clinical and epidemiological burden of chronic lymphocytic leukaemia.
@en
P2093
P2860
P1476
The clinical and epidemiological burden of chronic lymphocytic leukaemia.
@en
P2093
Botteman MF
Redaelli A
Stephens JM
P2860
P304
P356
10.1111/J.1365-2354.2004.00489.X
P407
P577
2004-07-01T00:00:00Z